Rationally Designed Ruthenium Complexes for Breast Cancer Therapy

Golbaghi, Golara et Castonguay, Annie ORCID: https://orcid.org/0000-0001-5705-6353 (2020). Rationally Designed Ruthenium Complexes for Breast Cancer Therapy Molecules , vol. 25 , nº 2: 265. pp. 1-25. DOI: 10.3390/molecules25020265.

Prévisualisation

PDF - Version acceptée Disponible sous licence Creative Commons Attribution. Télécharger (1MB) | Prévisualisation

Résumé

Since the discovery of the anticancer potential of ruthenium-based complexes, several species were reported as promising candidates for the treatment of breast cancer, which accounts for the greatest number of new cases in women every year worldwide. Among these ruthenium complexes, species containing bioactive ligand(s) have attracted increasing attention due to their potential multitargeting properties, leading to anticancer drug candidates with a broader range of cellular targets/modes of action. This review of the literature aims at providing an overview of the rationally designed ruthenium-based complexes that have been reported to date for which ligands were carefully selected for the treatment of hormone receptor positive breast cancers (estrogen receptor (ER+) or progesterone receptor (PR+)). In addition, this brief survey highlights some of the most successful examples of ruthenium complexes reported for the treatment of triple negative breast cancer (TNBC), a highly aggressive type of cancer, regardless of if their ligands are known to have the ability to achieve a specific biological function.

Type de document:	Article
Mots-clés libres:	breast cancer; enzyme inhibition; hormone positive breast cancer; metallodrug; multitargeted therapy; ruthenium; triple negative breast cancer (TNBC)
Centre:	Centre INRS-Institut Armand Frappier
Date de dépôt:	15 juill. 2021 14:44
Dernière modification:	14 févr. 2022 20:50
URI:	https://espace.inrs.ca/id/eprint/11589

Gestion Actions (Identification requise)

Modifier la notice